Furiex Pharmaceuticals, Inc.
3900 Paramount Parkway
Suite 150
Morrisville,
NC 27560
United States - Map
Phone: 919-456-7800
Website: http://www.furiex.com
| Index Membership: | N/A | | Sector: | Services | | Industry: | Business Services | | Full Time Employees: | 24 |
|
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The companys products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina. Key Statistics
| |
| | Pay | Exercised | Dr. Fredric N. Eshelman Pharm.D.,
64
Exec. Chairman, Vice Chairman of PPD and Chief Exec. Officer of PPD | 35.00K | N/A | Dr. June S. Almenoff M.D., Ph.D., F.A.C.P.,
56
Pres, Chief Medical Officer and Director | 565.00K | 0.00 | Mr. Marshall H. Woodworth ,
55
Chief Financial Officer, Principal Accounting Officer, Treasurer and Assistant Sec. | 335.00K | 0.00 | Dr. Paul S. Covington M.D.,
57
Sr. VP of Clinical Devel. and Operations | 413.00K | 0.00 | Dr. Gail F. McIntyre Ph.D., CH (ASCP), DABT,
50
Sr. VP of Research | 396.00K | 0.00 |
|
| | Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.14%